Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
British Journal of Haematology
|
May 10, 2018
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
Elizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, et al.
Leukemia
|
May 12, 2018
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing
Guangwu Guo, Noopur S Raje, Charles Seifer, et al.
Leukemia & Lymphoma
|
January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Leukemia
|
September 19, 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma
Julia Frede, Julia C Poller, Kayleen Shi, et al.
Blood Advances
|
December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Leukemia
|
January 14, 2022
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
Johannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, et al.
American Journal of Hematology
|
February 8, 2022
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
Peter O'Gorman, Jacob P Laubach, Michael E O'Dwyer, et al.
Blood Advances
|
June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Andrew R Branagan, Clifton Mo, Matthew Lei, et al.
British Journal of Haematology
|
January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
Artur Jurczyszyn, Jakub Radocha, Julio Davila, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
British Journal of Haematology
|
May 10, 2018
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
Elizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, et al.
Leukemia
|
May 12, 2018
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing
Guangwu Guo, Noopur S Raje, Charles Seifer, et al.
Leukemia & Lymphoma
|
January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
Artur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Leukemia
|
September 19, 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma
Julia Frede, Julia C Poller, Kayleen Shi, et al.
Blood Advances
|
December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Leukemia
|
January 14, 2022
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
Johannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, et al.
American Journal of Hematology
|
February 8, 2022
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
Peter O'Gorman, Jacob P Laubach, Michael E O'Dwyer, et al.
Blood Advances
|
June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Andrew R Branagan, Clifton Mo, Matthew Lei, et al.
British Journal of Haematology
|
January 10, 2018
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
Artur Jurczyszyn, Jakub Radocha, Julio Davila, et al.
Page
of 10